STOCK TITAN

Coastlands, Perry disclose 4.99% Eledon (ELDN) stake via amended 13G

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Coastlands-affiliated funds and Matthew D. Perry report minority ownership in Eledon Pharmaceuticals, Inc. on an amended Schedule 13G. Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Perry collectively report beneficial ownership of 3,937,826 shares of Eledon common stock, representing 4.99% of the class.

This position includes 450,000 shares held directly by Coastlands Capital LP and 3,487,826 shares issuable upon exercise of pre-funded warrants, all subject to a 4.99% beneficial ownership limitation. Perry’s reported beneficial ownership of 3,908,467 shares includes additional stock held through a trust. The filers state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Eledon.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Consists of 450,000 shares of Common Stock held directly by Coastlands Capital LP and 3,487,826 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP. The calculation of the beneficial ownership of the Reporting Persons is based on (A) (i) 79,630,297 shares outstanding as November 13, 2025, as provided by the Issuer to the Reporting Persons, less (ii) 4,203,764 shares of Common Stock exchanged for pre-funded warrants on December 30, 2025, and (B) 3,487,826 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 4.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation.


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of 450,000 shares of Common Stock held directly by Coastlands Capital LP and 3,487,826 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP. The calculation of the beneficial ownership of the Reporting Persons is based on (A) (i) 79,630,297 shares outstanding as November 13, 2025, as provided by the Issuer to the Reporting Persons, less (ii) 4,203,764 shares of Common Stock exchanged for pre-funded warrants on December 30, 2025, and (B) 3,487,826 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 4.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation.


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of 450,000 shares of Common Stock held directly by Coastlands Capital LP and 3,487,826 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP. The calculation of the beneficial ownership of the Reporting Persons is based on (A) (i) 79,630,297 shares outstanding as November 13, 2025, as provided by the Issuer to the Reporting Persons, less (ii) 4,203,764 shares of Common Stock exchanged for pre-funded warrants on December 30, 2025, and (B) 3,487,826 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 4.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation.


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of 450,000 shares of Common Stock held directly by Coastlands Capital LP and 3,487,826 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP. The calculation of the beneficial ownership of the Reporting Persons is based on (A) (i) 79,630,297 shares outstanding as November 13, 2025, as provided by the Issuer to the Reporting Persons, less (ii) 4,203,764 shares of Common Stock exchanged for pre-funded warrants on December 30, 2025, and (B) 3,487,826 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 4.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation.


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of 450,000 shares of Common Stock held directly by Coastlands Capital LP, 558,927 shares of Common Stock held directly by a trust for which Mr. Perry serves as co-trustee and 2,899,470 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP. The calculation of the beneficial ownership of the Reporting Persons is based on (A) (i) 79,630,297 shares outstanding as November 13, 2025, as provided by the Issuer to the Reporting Persons, less (ii) 4,203,764 shares of Common Stock exchanged for pre-funded warrants on December 30, 2025, and (B) 2,899,470 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 4.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation.


SCHEDULE 13G



Coastlands Capital LP
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer of the General Partner, Coastlands Capital LLC
Date:02/13/2026
Coastlands Capital Partners LP
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer of the General Partner, Coastlands Capital GP LLC
Date:02/13/2026
Coastlands Capital GP LLC
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer
Date:02/13/2026
Coastlands Capital LLC
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer
Date:02/13/2026
Matthew D. Perry
Signature:/s/ Matthew D. Perry
Name/Title:Reporting Person
Date:02/13/2026

Comments accompanying signature: Exhibit 99.1 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G (incorporated by reference from the Schedule 13D filed on November 24, 2025) https://www.sec.gov/Archives/edgar/data/1404281/000110465925115374/tm2531969d1_ex99-1.htm

FAQ

What percentage of Eledon Pharmaceuticals (ELDN) does Coastlands report owning?

Coastlands-affiliated entities report beneficial ownership of 4.99% of Eledon Pharmaceuticals’ common stock. This percentage is based on the issuer’s share count and includes both directly held shares and shares issuable upon exercise of pre-funded warrants, subject to a beneficial ownership cap.

How many Eledon Pharmaceuticals (ELDN) shares does Coastlands beneficially own?

Coastlands-related reporting persons disclose beneficial ownership of 3,937,826 Eledon common shares. This consists of 450,000 shares held directly and 3,487,826 shares issuable upon exercise of pre-funded warrants, calculated with a 4.99% beneficial ownership limitation in place.

What is Matthew D. Perry’s reported stake in Eledon Pharmaceuticals (ELDN)?

Matthew D. Perry reports beneficial ownership of 3,908,467 shares of Eledon common stock, or 4.99% of the class. His holdings include shares owned by Coastlands Capital LP, shares held in a trust where he is co-trustee, and shares issuable from pre-funded warrants.

How are Coastlands’ Eledon (ELDN) holdings structured between stock and warrants?

The Coastlands position includes 450,000 Eledon common shares held directly and 3,487,826 shares issuable upon exercise of pre-funded warrants. These warrants are subject to a 4.99% beneficial ownership limitation, which caps the exercisable amount at any time.

Why is the Eledon (ELDN) Schedule 13G/A filed as a passive ownership report?

The reporting persons certify the securities were acquired and are held in the ordinary course of business, not to change or influence control of Eledon. They also state the holdings are not part of any control-related transaction, consistent with a passive Schedule 13G filing.

Who ultimately benefits from the Eledon (ELDN) shares held by Coastlands?

The filing explains that the Partnership holds Eledon shares and warrants for the benefit of its investors. The Partnership has the right to receive dividends or sale proceeds, while Coastlands entities and Matthew D. Perry are reported as beneficial owners based on their pecuniary interests.
Eledon Pharmaceuticals Inc

NASDAQ:ELDN

ELDN Rankings

ELDN Latest News

ELDN Latest SEC Filings

ELDN Stock Data

160.06M
74.19M
1.4%
72.25%
7.25%
Biotechnology
Pharmaceutical Preparations
Link
United States
IRVINE